share_log

Vertex Pharmaceuticals | 8-K: Current report

Vertex Pharmaceuticals | 8-K: Current report

福泰制药 | 8-K：重大事件
美股sec公告 ·  05/20 08:40
Moomoo AI 已提取核心信息
On May 20, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts-based biotechnology company, announced the successful completion of its acquisition of Alpine Immune Sciences, Inc., a Delaware corporation. The acquisition, valued at approximately $5.0 billion in equity, was finalized following an agreement that was initially reported on April 11, 2024. The transaction was executed through a merger with Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., resulting in Alpine becoming a wholly owned subsidiary of Vertex. The accounting treatment for the acquisition is expected to be completed in the second quarter of 2024. This strategic move is part of Vertex's expansion plans and is subject to the usual risks and uncertainties associated with such forward-looking statements.
On May 20, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts-based biotechnology company, announced the successful completion of its acquisition of Alpine Immune Sciences, Inc., a Delaware corporation. The acquisition, valued at approximately $5.0 billion in equity, was finalized following an agreement that was initially reported on April 11, 2024. The transaction was executed through a merger with Vertex's wholly owned subsidiary, Adams Merger Sub, Inc., resulting in Alpine becoming a wholly owned subsidiary of Vertex. The accounting treatment for the acquisition is expected to be completed in the second quarter of 2024. This strategic move is part of Vertex's expansion plans and is subject to the usual risks and uncertainties associated with such forward-looking statements.
2024年5月20日，总部位于马萨诸塞州的生物技术公司Vertex Pharmicals Incorporated宣布成功完成对特拉华州公司Alpine Immune Sciences, Inc. 的收购。此次收购的股权价值约为50亿美元，是在最初于2024年4月11日公布的协议后完成的。该交易是通过与Vertex的全资子公司Adams Merger Sub, Inc. 的合并执行的，这使阿尔派成为Vertex的全资子公司。此次收购的会计处理预计将于2024年第二季度完成。这一战略举措是Vertex扩张计划的一部分，受与此类前瞻性陈述相关的常见风险和不确定性的影响。
2024年5月20日，总部位于马萨诸塞州的生物技术公司Vertex Pharmicals Incorporated宣布成功完成对特拉华州公司Alpine Immune Sciences, Inc. 的收购。此次收购的股权价值约为50亿美元，是在最初于2024年4月11日公布的协议后完成的。该交易是通过与Vertex的全资子公司Adams Merger Sub, Inc. 的合并执行的，这使阿尔派成为Vertex的全资子公司。此次收购的会计处理预计将于2024年第二季度完成。这一战略举措是Vertex扩张计划的一部分，受与此类前瞻性陈述相关的常见风险和不确定性的影响。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息